<p>CALGB 80303 was a randomized, phase III study in advanced pancreatic cancer patients treated with Gemcitabine plus either  Bevacizumab or placebo. No difference in overall survival (OS) was observed between the two arms. We prospectively collected  germline DNA and conducted a genome-wide association study (GWAS).</p>

CALGB 80303: Genome-Wide Association Study of Advanced Pancreatic Cancer    Patients

Pancreatic Neoplasms study with SNP Genotypes (Array) data on dbGaP (351 participants)